Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05173714 · ClinicalTrials.gov registry record · Phase 2
Sit Less, Interact and Move More (SLIMM) 2 Study
A Phase 2 study of Obesity and Chronic Kidney Diseases, sponsored by Srinvasan Beddhu.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 2
- Study locations
NCT05173714 is a Phase 2 study of Obesity and Chronic Kidney Diseases that is actively recruiting participants, run by Srinvasan Beddhu. The registered enrollment target is 156 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05173714, a Phase 2 study of Obesity and Chronic Kidney Diseases, is actively recruiting participants, sponsored by Srinvasan Beddhu.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 2
- Study locations
Study Summary
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
- BEHAVIORAL SLIMM
- BEHAVIORAL Standard Resistance Training
- BEHAVIORAL Guided Resistance Training
Study Locations (2)
California
- Stanford University - Stanford
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05173714
The ClinicalTrials.gov registry entry for NCT05173714 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (81% lower). The listed sponsor is Srinvasan Beddhu, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT05173714 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Utah.
Frequently Asked Questions
What is clinical trial NCT05173714 about?
NCT05173714 is a clinical study titled "Sit Less, Interact and Move More (SLIMM) 2 Study". * Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown th...
What is the current status of trial NCT05173714?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2021-12-01. Estimated completion is 2027-03-31.
What conditions does trial NCT05173714 study?
This clinical trial studies the following conditions: Obesity, Chronic Kidney Diseases.
What interventions are being tested in trial NCT05173714?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), SLIMM (BEHAVIORAL), Standard Resistance Training (BEHAVIORAL), Guided Resistance Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT05173714?
This trial is sponsored by Srinvasan Beddhu, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05173714 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.